AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00920764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75 mg Atrasentan QD
Description: 10 mL oral solution, daily, 8 weeks
Study NCT00920764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1.75 mg Atrasentan QD
Description: 10 mL oral solution, daily, 8 weeks
Study NCT00693199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine plus terazosin
Description: amlodipine 5 mg plus terazosin 2 mg once daily for 28days
Study NCT05529563 — intervention group
Intervention type: PROCEDURE
Intervention: LSG
Description: LSG
Study NCT03436355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The Active school study was a 10-month randomized controlled trial.The weekly interventions were 2×45 minutes physically active academic lessons, 5×10 minutes physically active breaks, and 5×10 minutes physically active homework.
Study NCT03871855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1702
Description: Administered IV
Study NCT03871855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Administered IV
Study NCT03948230 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Salt with / without water
Description: Drinks with and without a salt containing capsule
Study NCT03948230 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Salt with / without water
Description: Drinks with and without a salt containing capsule
Study NCT02848079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined TAS-102 and TAS-OX
Description: Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
Study NCT02023658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pMTCT systems analysis and improvement
Description: Five-step systems analysis and iterative improvement cycles carried out over a six-month period in intervention facilities.
Study NCT03902678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS guided fine needle aspiration of portal vein thrombus
Description: endoscopic ultrasound guided fine needle aspiration of portal vein thrombus which did not fulfill criteria of malignancy by imaging technique
Study NCT04460755 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study.
Study NCT04460755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste 1
Description: A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study.
Study NCT04460755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste 2
Description: A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study.
Study NCT04460755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste 3
Description: A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study.
Study NCT04460755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste 4
Description: A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study.
Study NCT04460755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste 5
Description: A sample of cells from the buccal mucosa area will be taken with cytological sampling brush and will be fixed on on a microscopy slide and stained with a Feulgen fast green solution. The samples will be analyzed by electron microscopy. Tooth color will be measured, verified and evaluated with a Vita Easyshade V digital spectrophotometer in initial phase, after one month of usage, after two months of usage and one month after the end of usage.~Before using any of the whitening toothpaste under test, every participant will use non whitening toothpaste for one month, twice a day.~Satisfaction and impression with treatment will be recorded with the questionnaires provided for this study.
Study NCT01864785 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fixation Combined With Fusion
Description: Articular process fusion with bone graft was carried out after screw fixation
Study NCT01864785 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fixation Alone
Description: Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
Study NCT02008825 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Utilization of ViSiGi calibration tube
Description: Utilization of ViSiGi calibration tube
Study NCT02008825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual non suction Bougie
Description: Usual non suction Bougie
Study NCT02969902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy® device
Study NCT02969902 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held computer
Study NCT03190187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulation
Description: Spinal manipulation based on orthopaedic manual therapy approach
Study NCT03190187 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham manipulation
Description: Patients will receive simulated spinal manipulation without force application
Study NCT00135304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensipar®
Description: Cinacalcet hydrochloride
Study NCT00135304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D administered IV
Study NCT00135304 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D administered IV
Study NCT00805740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active anidulafungin
Description: Subjects in this arm will receive active anidulafungin and placebo caspofungin
Study NCT00805740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Caspofungin
Description: Subjects in this arm will receive active caspofungin and placebo anidulafungin
Study NCT03881007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash with LCM
Description: Subjects will mouthwash daily with LCM and before/after sex
Study NCT03881007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mouthwash with placebo
Description: Subjects will mouthwash daily with placebo and before/after sex
Study NCT04954807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: human milk fortified
Description: HMF will be given 6 scoops a day
Study NCT04954807 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be given six scoops a day
Study NCT01072409 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nucleus 5 Cochlear implant
Description: Cochlear implant surgery
Study NCT01072409 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cochlear implantation
Description: Implantation
Study NCT04181879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: * GPs allocated to the intervention will be given access to the intervention package and asked to perform medication reviews with approximately 10 patients on two occasions (initial and 6-months follow-up).~* The intervention package consists of two components: (a) an online video demonstrating how GPs can improve appropriate polypharmacy during typical consultations with older patients; (b) a patient recall process (appointment with the GP for a medication review).~* GPs will be asked to schedule appointments with consenting patients (telephone or online consultations where a face-to-face consultation is not possible). During these appointments, GPs will undertake medication reviews ('a structured, critical examination of a person's medicines with the objective of reaching an agreement with the person about treatment, optimising the impact of medicines, minimising the number of medication-related problems and reducing waste').
Study NCT01047202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza A/H1N1 vaccine
Description: Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
Study NCT01047202 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza A/H1N1 vaccine
Description: Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
Study NCT01047202 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Seasonal trivalent vaccine
Description: Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
Study NCT02983487 — intervention group
Intervention type: PROCEDURE
Intervention: Nasopharyngeal sampling
Description: Nasopharyngeal sample by aspiration or swabbing
Study NCT02983487 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Sampling
Description: Blood sample by the tip of a finger (fingerprick)
Study NCT02892266 — intervention group
Intervention type: OTHER
Intervention: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
Study NCT01495494 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed Nasal Strip
Description: Breathe Right Nasal Strips - Clear small/medium strip
Study NCT01495494 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype Nasal Dilator
Description: Prototype Nasal Dilator AB2R11
Study NCT03201055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Snore PAP System
Description: The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
Study NCT03569202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piiloset Trehalose Emulsion Eye Drops
Description: Topical application of preservative-free multidose Piiloset Trehalose Emulsion Eye Drops 3 times daily
Study NCT03569202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Eye Drops
Description: Topical application of preservative-free multidose Hyaluronic Acid Eye Drops 3 times daily
Study NCT01859377 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: V0498 - A mg
Description: Single oromucosal administration
Study NCT01859377 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ibuprofen
Description: Single oral administration
Study NCT02932787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Height-adjustable workstation
Study NCT05773404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Neurodynamics and Passive axial hip mobilisation/distraction
Description: The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles.
Study NCT05773404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active therapy
Description: Active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves
Study NCT05773404 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2.5.3. Combined therapy
Description: The physiotherapist performs passive techniques on the hamstring muscles and the nerve that innervates the hamstring muscles and active lumbopelvic CORE control exercises and active stretching of the ischiopelvic nerves.
Study NCT03575104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant will be administered as tablets, orally, once daily in the evening.
Study NCT03575104 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablets, orally, once daily in the evening.
Study NCT03932994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACT on Health
Description: This intervention consists of an online canvas course based on Acceptance and Commitment Therapy, focused on increasing healthy diet and physical activity and addressing barriers to change. The intervention also consists of weekly phone coaching calls.
Study NCT02665429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual prescribing data profile and self-assessment
Description: Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
Study NCT01087541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational program 6-hour standardized
Description: 6-hour standardized program for adults ( doctors and nurses )
Study NCT00254410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
Study NCT00254410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
Study NCT00254410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
Study NCT00254410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
Study NCT00254410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
Study NCT03390179 — intervention group
Intervention type: DRUG
Intervention: Steroid Drug
Description: mesure of the glucose concentration
Study NCT04248205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Standard general anesthesia PLUS ketamine will be given for post-operative analgesia
Study NCT05370573 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Observational - no interventions
Study NCT03094000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIND
Description: Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .~The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP).
Study NCT03094000 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-E
Description: The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
Study NCT03094000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-E
Description: The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
Study NCT01471665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
Study NCT01471665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once daily for up to 16 days.
Study NCT01742260 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair of cranial defects by tissue engineering
Description: Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
Study NCT02975830 — intervention group
Intervention type: RADIATION
Intervention: Three dimensional CT based images
Description: Right bronchial angle, left bronchial angle
Study NCT00584233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).
Study NCT00584233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Breast MRI
Study NCT02222714 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3K3A-APC
Description: 3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
Study NCT02222714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
Study NCT00732173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Undergo SUCCEED lifestyle intervention
Study NCT00732173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Undergo SUCCEED lifestyle intervention
Study NCT00732173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo SUCCEED lifestyle intervention
Study NCT00732173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Receive information
Study NCT00732173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: educational intervention
Description: Receive information
Study NCT00732173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Undergo SUCCEED lifestyle intervention
Study NCT03100903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130
Description: single dose